Evidence map›Paper›PMID 22982629›Full record

ArticleThe Journal of steroid biochemistry and molecular biology2013

1,25(OH)(2)vitamin D(3) enhances myogenic differentiation by modulating the expression of key angiogenic growth factors and angiogenic inhibitors in C(2)C(12) skeletal muscle cells.

Leah A Garcia, Monica G Ferrini, Keith C Norris, Jorge N Artaza

Open access · greenAbstract read
In one paragraph

Article in The Journal of steroid biochemistry and molecular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Vitamin D, a modulator of musculoskeletal health in chronic kidney disease.Journal of cachexia, sarcopenia and muscle · 2017
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Leah A GarciaDepartment of Internal Medicine, Charles R. Drew University of Medicine & Science, Los Angeles, CA 90059, USA.
Monica G Ferrini
Keith C Norris
Jorge N Artaza
Charles R. Drew University of Medicine and Science · USUniversity of California, Los Angeles · US

Funding

Sustaining Faculty Development & Community EngagementS21MD000103 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI CARLISLE, DAVID M · 2001 to 2015
$73.9M
Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Piwen Wang · 2012 to 2026
$60.0M
STEERING COMMITTEEU54MD008149 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI OFILI, ELIZABETH O. · 2012 to 2018
$21.1M
THE NUTRIGENOMICS OF VITAMIN D METABOLISM IN AFRICAN-AMERICANSU54RR022762 · NCRR · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI NORRIS, KEITH C · 2007 to 2011
$19.6M
TRAINING COREP20MD000182 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI CUNNINGHAM, WILLIAM EMERY, SHAPIRO, MARTIN F. · 2002 to 2016
$16.5M
VITAMIN D STIMULATES CARDIAC DIFFERENTIATIONU54RR026138 · NCRR · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI NORRIS, KEITH C · 2009 to 2011
$14.0M
Nitric Oxide/cGMP Modulation of Corporal Fibrosis Caused by NeuropraxiaSC1NS064611 · NINDS · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI FERRINI, MONICA GABRIELA · 2008 to 2012
$1.4M
NCRR NIH HHS RR022762NCRR NIH HHS RR026138NCRR NIH HHS U54 RR022762NCRR NIH HHS U54 RR026138NIMHD NIH HHS MD000103NIMHD NIH HHS MD000182NIMHD NIH HHS P20 MD000182NIMHD NIH HHS S21 MD000103NIMHD NIH HHS U54 MD007598NIMHD NIH HHS U54 MD008149NINDS NIH HHS SC1 NS064611NINDS NIH HHS SC1NS064611
6 · The paper itself

Abstract

Vitamin D is mostly recognized for its regulation of calcium homeostasis in relation to the intestine, kidney, and bone. Although clinical studies have linked vitamin D with increased muscle function and strength, little is known of its underlying molecular mechanism. We recently demonstrated that 1,25-D3 exerts a direct pro-myogenic effect on skeletal muscle cells; this has provoked our investigation of 1,25-D's effect on angiogenesis, a vital process for new capillary development and tissue repair. In this study, we examined the mechanism by which 1,25-D3 modulates key angiogenic growth factors and angiogenic inhibitors. C(2)C(12) myoblasts were incubated with 100 nM 1,25-D3 or placebo for 1, 4 and 10 days. At the end of the respective incubation time, total RNA was isolated for PCR arrays and for qRT-PCR. Total proteins were isolated for Western blots and proteome profiler arrays. The addition of 1,25-D3 to C(2)C(12) myoblasts increased VEGFa and FGF-1: two pro-angiogenic growth factors that promote neo-vascularization and tissue regeneration, and decreased FGF-2 and TIMP-3: two myogenic and/or angiogenic inhibitors. Our previous study demonstrated that 1,25-D3 altered IGF-I/II expression, consistent with the observed changes in VEGFa and FGF-2 expression. These results extend our previous findings and demonstrate the modulation of angiogenesis which may be an additional mechanism by which 1,25-D3 promotes myogenesis. This study supports the mechanistic rationale for assessing the administration of vitamin D and/or vitamin D analogs to treat select muscle disorders and may also provide an alternative solution for therapies that directly manipulate VEGF and FGF's to promote angiogenesis.

Indexed as

AnimalsCalcitriolCell DifferentiationCell LineFibroblast Growth Factor 1Fibroblast Growth Factor 2Gene Expression Regulation, DevelopmentalMiceMuscle DevelopmentMuscle Fibers, SkeletalNeovascularization, PhysiologicRNA, MessengerTissue Inhibitor of Metalloproteinase-3Vascular Endothelial Growth Factor ACalcitriolFibroblast Growth Factor 1Fibroblast Growth Factor 2RNA, MessengerTissue Inhibitor of Metalloproteinase-3Vascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID22982629
PMCPMC3513642
OpenAlexW2120395943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.